Analyst Research

Report Title Price
Provider: Directors Deals Ltd.
$12.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nobel Biocare Holding AG comments on FY 2014 sales outlook and raises FY 2014 EBIT outlook


Thursday, 21 Aug 2014 12:45am EDT 

Nobel Biocare Holding AG:Says underlying operating profit (EBIT) margin outlook raised for the full year 2014 and the 3-5 year term.Expects FY 2014 revenue to grow around 3 pct to 4 pct (CER) and to improve EBIT margin excluding realignment costs by about 150-200 bps (CER) from 12.1 pct in 2013 (previous outlook was 100 bps CER).Says over the next 3-5 years, and given the progress of the company, EBIT margin improvement outlook is raised to 100-150 bps at CER per year (from 50-100 bps as communicated earlier).FY 2013 revenue of 566.79 million euros.FY 2014 revenue estimate 572.24 million euros - Thomson Reuters I/B/E/S. 

Company Quote

17.1
0.0 +0.00%
19 Dec 2014